UNIVERSITY OF CEBU-BANILAD

COLLEGE OF NURSING

DRUG STUDY

Patient: A.R.B Age: 50 years old Hospital No. Room No. Renal

Impression/Diagnosis: Acute Pyelonephritis with Ureterolithiasis, Acute Kidney Injjury Attending Physician(s): Dr. Ariel Indo

Allergy to: None

Generic/ Brand Name & Dosage Timing & Duration Indication/Pharmacodynamics of Drug Side Effects/ Adverse Nursing Responsibilities Patient Teaching
Classification Reaction/ Contraindication
(5%) (20%) (Nursing Process Approach) (20 %)
(5％) (10%)
(40%)

Generic Name: Drug form & Dosage Indications: Side Effects: Assessment  Inform patient that a gout
Ordered: attack may occur when
Febuxostat Chronic management of hyperuricemia in pts Rare (1%): Nausea, arthralgia, Assess baseline renal function,
febuxostat therapy starts
40 mg with gout. rash, dizziness. LFT; concomitant use with
and that colchicine or an
azaTHIOprine,
(Kizior & Hodgson, 2021) NSAID may be prescribed,
mercaptopurine, theophylline
Adverse Effects: usually along with
(contraindicated).
febuxostat, to treat it.
Brand Name: Pharmacodynamics Hepatic function abnormalities  Instruct patient to seek
Interventions
Timing: occur in 6% of pts. May immediate emergency care
Urica Inhibits the action of xanthine oxidase, the key increase risk of  Discontinue medication for signs or symptoms of a
Once every other day enzyme responsible for purine breakdown. thromboembolic events immediately if rash heart attack or stroke.
Xanthine oxidase catalyzes conversion of
including CVA, MI. appears. Encourage high  Tell patient that periodic
xanthine to uric acid, thereby increasing uric
acid levels. High uric acid levels cause gout fluid intake (3,000 blood tests will be needed
Classification Name: attacks. Inhibiting xanthine oxidase causes mL/day). to determine drug’s
Pharmacologic class: uric acid levels to drop, decreasing the risk of Contraindication:  Monitor I&O (output effectiveness and to detect
Xanthine oxidase inhibitor Duration: gout attack. Hypersensitivity to febuxostat. should be at least 2,000 adverse effects.
(Jones & Bartlett, 2021) Concomitant use with mL/day).  Advise patient to notify
Therapeutic class: Antigout Unknown
azaTHIOprine, mercaptopurine.  Monitor CBC, serum uric prescriber at first sign of a
Pharmacokinetics Cautions: Severe renal/hepatic acid, renal function, LFT. rash or other skin
impairment, history of heart  Assess urine for abnormality.
Well absorbed from GI tract. Widely cloudiness, unusual color,
disease or stroke. (Jones & Bartlett, 2021)
distributed. odor.
Hypersensitivity to allopurinol.
Protein binding: 99%. Pts at risk for urate formation.  Assess for therapeutic
response (reduced joint
Metabolized in liver. (Kizior & Hodgson, 2021) tenderness, swelling,
Excreted in urine (49%), feces (45%). redness, limitation of
Other drug forms: Removed by hemodialysis. motion).
 Monitor for symptoms of
 Tablets: 80 mg Half-life: 5–8 hrs. CVA, MI.
(Kizior & Hodgson, 2021)
(Kizior & Hodgson, 2021)

___Mr. Barlutch Centillas, MAN, RN__ _______CLAIRE MAURICE G. JUANERO_____

Printed Name and Signature Printed Name and Signature
Clinical Instructor Student

UNIVERSITY OF CEBU-BANILAD
 COLLEGE OF NURSING

DRUG STUDY

Patient: A.R.B Age: 50 years old Hospital No. Room No. Renal

Impression/Diagnosis: Acute Pyelonephritis with Ureterolithiasis, Acute Kidney Injjury Attending Physician(s): Dr. Ariel Indo

Allergy to: None

Generic/ Brand Name & Dosage Timing & Duration Indication/Pharmacodynamics of Drug Side Effects/ Adverse Nursing Responsibilities Patient Teaching
Classification Reaction/ Contraindication
(5%) (20%) (Nursing Process Approach) (20 %)
(5％) (10%)
(40%)

Generic Name: Drug form & Dosage Indications: Side Effects: Assessment  Tell patient prescribed oral
Ordered: solution to take it 1 hour
Levofloxacin To reduce incidence or progression of Occasional (3%–1%): Diarrhea,  Question for before or 2 hours after
500 mg inhalation anthrax after exposure to nausea, abdominal pain, hypersensitivity to eating.
aerosolized Bacillus anthracis; to treat plague, dizziness, drowsiness, levofloxacin, other  Advise patient to increase
including pneumonic and septicemic plague, headache. fluoroquinolones. Question fluid intake during therapy
caused by Yersinia pestis; to provide history as listed in to prevent crystalluria.
Ophthalmic: Local
prophylaxis for plague. Precautions. Receive full  Direct patient to take an
Brand Name: burning/discomfort, margin
medication history, and antacid, didanosine, iron,
Timing: (Jones & Bartlett, 2021) crusting, crystals/scales,
screen for interactions, esp. sucralfate, or zinc at least 2
foreign body sensation, ocular hours before or after
Once every other day medications that prolong
itching, altered taste. levofloxacin.
Pharmacodynamics QT interval. Obtain
Rare (less than 1%): baseline ECG.  Tell patient to complete the
Interferes with bacterial cell replication by drug as prescribed, even if
Classification Name: Flatulence; pain, inflammation,
inhibiting the bacterial enzyme DNA gyrase, Interventions symptoms subside.
which is essential for repair and replication of swelling in calves, hands,  Urge patient to avoid
Pharmacologic class: shoulder; chest pain, difficulty  Monitor serum glucose,
bacterial DNA. excessive sun exposure and
Fluoroquinolone Duration:
(Jones & Bartlett, 2021) breathing, palpitations, edema, renal function, LFT. to wear sunscreen because
Therapeutic class: Antibiotic tendon pain.  Monitor daily pattern of of increased risk of
Pharmacokinetics Ophthalmic: Corneal staining, bowel activity, stool photosensitivity.
keratitis, allergic reaction, consistency.  Tell patient to notify
Well absorbed after PO, IV administration. prescriber at first sign of
eyelid swelling, tearing,  Promptly report
hypersensitivity reaction: photosensitivity.
Protein binding: 50%. reduced visual acuity.
skin rash, urticaria,  Caution patient to avoid
Widely distributed. Excreted unchanged in Adverse Effects: hazardous activities until
pruritus, photosensitivity.
urine. Partially removed by hemodialysis. drug’s CNS effects are
 Antibiotic-associated  Be alert for superinfection: known.
Half-life: 6–8 hrs. colitis, other fever, vomiting, diarrhea,  Tell patient to stop drug
superinfections (abdominal anal/genital pruritus, oral and notify prescriber if he
Other drug forms: (Kizior & Hodgson, 2021)
cramps, severe watery mucosal changes develops abnormal
Infusion Premix: 250 mg/50 diarrhea, fever) may occur. (ulceration, pain, changes in motor or
mL, 500 mg/100 mL, 750  Superinfection (genital/anal erythema). sensory function, or if he
mg/150 mL.
Injection, Solution: 25 mg/mL.
Ophthalmic Solution: 0.5%.
Oral Solution: 25 mg/mL.
 Hypersensitivity reactions,
Tablets: 250 mg, 500 mg, 750
mg.
Contraindication:
pruritus, ulceration/changes 
in oral mucosa, moderate to
severe diarrhea) may occur
from altered bacterial
balance in GI tract.
including photosensitivity
(rash, pruritus, blisters,
edema, sensation of burning
skin), have occurred in pts
receiving fluoroquinolones.
May increase risk of
tendonitis, tendon rupture,
peripheral neuropathy; CNS
effects including agitation,
anxiety, confusion,
depression, dizziness,
hallucinations, nightmares,
paranoia, tremors, vertigo.
May exacerbate muscle
weakness in pts with
myasthenia gravis.
 Hypersensitivity to
levofloxacin, other
fluoroquinolones.
(Kizior & Hodgson, 2021)
Monitor for muscle experiences bruising right
weakness, voice dystonia after an injury in a tendon
area, hearing or feeling a
in pts with myasthenia
gravis; pain, swelling, pop or snap in a tendon
bruising, popping of area, or is unable to move
the affected area or bear
tendons.
weight.
(Kizior & Hodgson, 2021)  Inform patient tendon
problems may be
permanent.
 Urge patient experiencing
a rash or other allergic
reactions to stop drug and
tell prescriber.
 Urge patient to notify
prescriber if patient
experiences pain or
tenderness in the upper
right side of the abdomen.
 Advise diabetic patient to
monitor blood glucose
level and report changes.
 Urge patient to tell
prescriber about severe
diarrhea, even if it’s more
than 2 months after drug
therapy ends. Additional
treatment may be needed.
 Advise patient to notify
prescriber about heart
palpitations or loss of
consciousness.
 Advise patient to stop
taking levofloxacin
immediately and notify
prescriber if any persistent,
serious, or worsening
adverse effects occur.
(Jones & Bartlett, 2021)
___Mr. Barlutch Centillas, MAN, RN__ _______CLAIRE MAURICE G. JUANERO_____
Printed Name and Signature Printed Name and Signature
Clinical Instructor Student

UNIVERSITY OF CEBU-BANILAD

COLLEGE OF NURSING
 DRUG STUDY

Patient: A.R.B Age: 50 years old Hospital No. Room No. Renal

Impression/Diagnosis: Acute Pyelonephritis with Ureterolithiasis, Acute Kidney Injjury Attending Physician(s): Dr. Ariel Indo

Allergy to: None

Generic/ Brand Name & Dosage Timing & Duration Indication/Pharmacodynamics of Drug Side Effects/ Adverse Nursing Responsibilities Patient Teaching
Classification Reaction/ Contraindication
(5%) (20%) (Nursing Process Approach) (20 %)
(5％) (10%)
(40%)

Generic Name:
Tamsulosin
Brand Name:
Classification Name:
Pharmacologic class: Alpha
adrenergic antagonist
Therapeutic class: Benign
prostatic hyperplasia (BPH)
agent
Pregnancy category: B
Drug form & Dosage Indications: Side Effects: Assessment  Instruct patient not to
Ordered: chew, crush, or open
Treatment of symptoms of benign prostatic Frequent (9%–7%): Dizziness,  Assess history of prostatic tamsulosin capsules and to
400 mg hyperplasia (BPH). drowsiness. hyperplasia (difficulty take drug about 30 minutes
(Kizior & Hodgson, 2021) initiating urine stream, after the same meal each
Occasional (5%–3%):
dribbling, sense of day.
Headache, anxiety, insomnia,
urgency, leaking).  Instruct patient to notify
orthostatic hypotension.
 Question for sensitivity to prescriber if he misses
Pharmacodynamics several days of therapy,
Rare (less than 2%): Nasal tamsulosin, or use of other
Timing: and caution him against
Blocks alpha1-adrenergic receptors in the congestion, pharyngitis, alpha-adrenergic blocking
OD rhinitis, nausea, vertigo, agents. restarting drug at previous
prostate. This action inhibits smooth muscle
impotence. dosage.
contraction in the bladder neck and prostate,  Obtain vital signs.
 Advise patient to avoid
prostatic capsule, and prostatic urethra, which
potentially hazardous
improves the rate of urine flow and reduces activities until drug’s CNS
symptoms of BPH. Adverse Effects: Interventions
effects are known.
Duration: (Jones & Bartlett, 2021) First-dose syncope
 Assist with ambulation if
 Mention the need for
(hypotension with sudden loss caution if dosage is
dizziness occurs.
of consciousness) may occur increased.
Pharmacokinetics  Monitor renal function,  Advise patient to change
within 30–90 min after initial
I&O, weight changes, position slowly, especially
Well absorbed, widely distributed. dose. May be preceded by
peripheral edema, B/P. after initial dose and each
tachycardia (pulse rate of 120–
Protein binding: 94%–99%.  Monitor for first-dose dosage increase, to
160 beats/min).
syncope. minimize effects of
Metabolized in liver. Primarily excreted in orthostatic hypotension.
urine. Unknown if removed by hemodialysis. (Kizior & Hodgson, 2021)  Tell patient to inform
Contraindication:
Half-life: 9–13 hrs. ophthalmologist of
Hypersensitivity to tamsulosin. tamsulosin therapy because
Other drug forms: (Kizior & Hodgson, 2021) drug may increase risk for
(Kizior & Hodgson, 2021) complications with cataract
Tablets: 80 mg surgery.

(Jones & Bartlett, 2021)

___Mr. Barlutch Centillas, MAN, RN__ _______CLAIRE MAURICE G. JUANERO_____
Printed Name and Signature Printed Name and Signature
Clinical Instructor Student